These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 21968939

  • 1. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.
    Prostate; 2012 Jun 01; 72(8):856-67. PubMed ID: 21968939
    [Abstract] [Full Text] [Related]

  • 2. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K, Suzuki K.
    Biochem Biophys Res Commun; 2012 Mar 16; 419(3):584-9. PubMed ID: 22387542
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2009 Jun 16; 16(2):401-13. PubMed ID: 19153211
    [Abstract] [Full Text] [Related]

  • 6. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H, Klotz LH, Sugar LM, Kiss A, Venkateswaran V.
    Biochem Biophys Res Commun; 2015 Aug 28; 464(3):848-54. PubMed ID: 26182875
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
    Sakai I, Miyake H, Terakawa T, Fujisawa M.
    Cancer Sci; 2011 Apr 28; 102(4):769-75. PubMed ID: 21214673
    [Abstract] [Full Text] [Related]

  • 8. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, Kim CS.
    J Urol; 2010 Dec 28; 184(6):2557-64. PubMed ID: 21030039
    [Abstract] [Full Text] [Related]

  • 9. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
    Musende AG, Eberding A, Jia W, Ramsay E, Bally MB, Guns ET.
    Prostate; 2010 Sep 15; 70(13):1437-47. PubMed ID: 20687217
    [Abstract] [Full Text] [Related]

  • 10. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ.
    Int J Cancer; 2009 Dec 01; 125(11):2711-20. PubMed ID: 19530253
    [Abstract] [Full Text] [Related]

  • 11. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
    Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R.
    Prostate; 2012 Nov 01; 72(15):1648-58. PubMed ID: 22473873
    [Abstract] [Full Text] [Related]

  • 12. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM.
    Anticancer Res; 2004 Nov 01; 24(5A):2897-903. PubMed ID: 15517894
    [Abstract] [Full Text] [Related]

  • 13. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.
    J Cell Physiol; 2007 May 01; 211(2):533-43. PubMed ID: 17192846
    [Abstract] [Full Text] [Related]

  • 14. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N, Schwarz MA, Schwarz RE.
    Cancer Chemother Pharmacol; 2011 Sep 01; 68(3):571-82. PubMed ID: 21110024
    [Abstract] [Full Text] [Related]

  • 15. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X, Wu JB, Chung LW, Huang WC.
    Oncotarget; 2015 Dec 01; 6(38):41018-32. PubMed ID: 26512780
    [Abstract] [Full Text] [Related]

  • 16. 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.
    Minelli A, Bellezza I, Tucci A, Conte C, Bracarda S, Culig Z.
    Prostate; 2008 Mar 01; 68(4):360-72. PubMed ID: 18189232
    [Abstract] [Full Text] [Related]

  • 17. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.
    Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD.
    Prostate; 2008 Nov 01; 68(15):1635-46. PubMed ID: 18668525
    [Abstract] [Full Text] [Related]

  • 18. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
    Freitas M, Alves V, Sarmento-Ribeiro AB, Mota-Pinto A.
    Biochem Biophys Res Commun; 2011 May 20; 408(4):713-9. PubMed ID: 21549092
    [Abstract] [Full Text] [Related]

  • 19. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
    Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G.
    Anticancer Drugs; 2006 Aug 20; 17(7):807-13. PubMed ID: 16926630
    [Abstract] [Full Text] [Related]

  • 20. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
    Gan L, Wang J, Xu H, Yang X.
    Prostate; 2011 Aug 01; 71(11):1158-66. PubMed ID: 21656826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.